Yearly update of advances in. medical oncology

Yearly update of advances in medical oncology May 27-28 2016 Royal Olympic Hotel Athens Οργάνωση Θα χορηγηθούν 12 μόρια Συνεχιζόμενης Ιατρικής Εκπαίδευσης (CME - CPD credits) Υπό την αιγίδα Εταιρεία Ογκολόγων Παθολόγων Ελλάδος ΕΟΠΕ Ελληνική Εταιρεία Ακτινοθεραπευτικής Ογκολογίας Ελληνική Εταιρεία Ανοσο-Ογκολογίας Ελληνική Εταιρεία Χειρουργικής Ογκολογίας The work generates ideas Science mind volition Imagination determination knowledge action inventiveness development cooperation The work generates idea

Πρόλογος Αγαπητοί συνάδελφοι και φίλοι, Με ιδιαίτερη χαρά σας προσκαλούμε στη Διημερίδα με τίτλο «Yearly update of Advances in Medical Oncology 2015» που διοργανώνεται από την Ελληνική Ογκολογική Ερευνητική Ομάδα, στις 27-28 Μαΐου 2016 στο ξενοδοχείο Royal Olympic, Athens. Το σύνολο της ετήσιας δημοσιευόμενης βιβλιογραφίας που αφορά στην ογκολογία είναι τεράστια και, ως εκ τούτου, πολύ προβληματική, η σε βάθος παρακολούθησή της. Αποφασίσθηκε να παρουσιασθούν και να αναλυθεί η προοπτική των πιο σημαντικών ογκολογικών μελετών που έχουν δημοσιευθεί σαν πλήρη άρθρα σε υψηλού impactfactor περιοδικά μέσα στο 2015, σε ένα εντατικό 2ημερο. Η εκπαιδευτική αυτή εκδήλωση, η οποία αφορά σε όλους τους ασχολούμενους με τον καρκίνο και τον ογκολογικό ασθενή, πραγματοποιείται για πρώτη φορά στην Ελλάδα και φιλοδοξεί να αναδειχθεί σε μία ουσιαστική εκπαιδευτική διαδικασία που θα συμπληρώνει το φάσμα και το εύρος της συνεχιζόμενης εκπαίδευσης στην κλινική και εργαστηριακή ογκολογία. Μία ομάδα έμπειρων συναδέλφων, επέλεξαν άρθρα, που δίνουν προοπτικές για σημαντικές άμεσες ή επικείμενες εξελίξεις στην ογκολογία, οι οποίες θα μπορούσαν να αλλάξουν την καθημερινή πρακτική. Ως εκ τούτου, ο στόχος είναι μέσω της αναλυτικής παρουσίασης των μελετών να επιτευχθεί μία περισσότερο λεπτομερειακή ενημέρωση, να βελτιωθεί η κλινική γνώση και, βέβαια, η ποιότητα της καθημερινής πρακτικής. Ελπίζουμε ότι οι όποιες αδυναμίες και ατέλειες παρουσιασθούν να κριθούν με θετικό πνεύμα και να μας υποδειχθούν προκειμένου να μπορέσουμε να επιτύχουμε το μέγιστο δυνατό αποτέλεσμα στην προσπάθειά μας. Με εγκάρδιους χαιρετισμούς, Βασίλης Γεωργούλιας Επιστημονική Επιτροπή Πρόεδρος Β. Γεωργούλιας Μέλη Α. Αργύρης Μ. Βασλαματζής Α. Βουτσινά Χ. Εμμανουηλίδης Ο. Κατωπόδη Ν. Κεντεποζίδης Α. Κουμαριανού Α. Κούτρας Α. Κουτσόπουλος Α. Κωτσάκης Ε. Λιανίδου Θ. Μακατσώρης Α. Μπάμιας Ι. Μπουκοβίνας Σ. Ξυνόγαλος Χ. Πανόπουλος Χ. Παπαδημητρίου Α. Πολύζος Ε. Σαλούστρος Ε. Τιμοθεάδου Μ. Τριχάς Ο. Τσιτσιλώνη Α. Χριστοπούλου Χ. Χριστοφυλλάκης Ομότιμος Καθηγητής Παθολογίας-Ογκολογίας Πανεπιστημίου Κρήτης 03

Scientific Program 11.15-11.30 PIK3CA Mutations are Associated with Decreased N. Tsoukalas Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Breast Cancer FRIDAY, May 27th, 2016 08.00-09.00 Registration 09.00-09.45 Session 1: General Issues Ι Moderator: M. Vaslamatzis, A. Polyzos 09.00-09.15 Drug drug interactions in patients treated for cancer: a prospective study on clinical Interventions E. Ntouvelis A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas 09.15-09.30 Relationship Between Male Pattern Baldness and M. Bakogeorgos the Risk of Aggressive Prostate Cancer: An Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Indicators of integration of oncology and palliative care programs: an international consensus 09.30-09.45 09.45-10.30 Session 2: Early trials Moderator: Ch. Emmanouilides, A. Κoumarianou 09.45-10.00 Safety and Efficacy of Buparlisib (BKM120) in G. Oikonomopoulos Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study A phase I/II, open-label, randomised study of nintedanib plus mfolfox6 versus bevacizumab plus mfolfox6 in first-line metastatic colorectal cancer patients 10.00-10.15 Phase I study of every 2- or 3-week dosing of ramucirumab, K. Rapti a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment 10.15-10.30 10.30-11.00 Coffee break 11.00-12.00 Session 3: Biomarkers I Moderators: Th. Makatsoris, E. Saloustros 11.00-11.15 Substantial contribution of extrinsic risk factors to cancer development S. Boussios Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F 04 Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit from Adjuvant Trastuzumab in the NSABP B-31 Trial 11.30-11.45 Gene Expression Markers of Efficacy and Resistance to K. Tsigaridas Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance) Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer 11.45-12.00 12.00-13.00 Session 4: Biomarkers II Moderators: A. Voutsina, A. Koutsopoulos 12.00-12.15 Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas F. Koinis Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung 12.15-12.30 Detection and Dynamic Changes of EGFR Mutations from M. Nikolaou Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy EGFR Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients EGFR 12.30-12.45 Massively Parallel Sequencing Identifies Recurrent G. Fotopoulos Mutations in TP53 in Thymic Carcinoma Associated with Poor Prognosis EGFR Kinase Domain Duplication ( EGFR -KDD) is a Novel Oncogenic Driver in Lung Cancer that is Clinically Responsive to Afatinib 12.45-13.00 13.00-14.00 Lunch 14.00-15.15 Session 5: Circulating biomarkers (CTcs and CtDNA) Moderator: E. Lianidou, A. Koutras 14.00-14.15 Can Circulating Tumor Cells Predict Resistance in Metastatic Breast Cancer? F. Zagouri Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019 14.15-14.30 Androgen receptor expression in circulating tumour J. Dimitriadis cells from castration-resistant prostate cancer patients treated with novel endocrine agents 05

Translational Implications of Tumor Heterogeneity CTCs 14.30-14.45 Androgen Receptor Gene Aberrations in Circulating E. Kostouros Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer 14.45-15.00 Epithelial Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression N. Pistamaltzian Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer 15.00-15.15 15.15-15.45 Coffee break 15.45-16.30 Session 6: Melanoma, Sarcomas Moderator: Ι. Boukovinas, Ch. Panopoulos 15.45-16.00 Randomized phase II study evaluating veliparib A. Laskarakis (ABT-888) with temozolomide in patients with metastatic melanoma A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival 16.00-16.15 Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents E. Voulgaris Clinically Relevant Molecular Subtypes in Leiomyosarcoma 16.30-17.30 Session 7: Gerniturinary tumors Moderator: A. Bamias, S. Xynogalos K. Loga IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma 16.45-17.00 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer 17.15-17.30 17.30-18.00 Coffee break 18.00-19.00 Session 8: Upper GI tumors Moderator: N. Kentepozidis, O. Katopodis 18. 00-18.15 Phase III study comparing oxaliplatin plus S-1 with K. Laschos cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma 18.15-18.30 Optimal Patient Selection for Trastuzumab K. Ploiarchopoulou Treatment in HER2-Positive Advanced Gastric Cancer A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer 18.30-18.45 Precision Medicine for Advanced Pancreas Cancer: A. Tzovaras The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma 18.45-19.00 16.15-16.30 16.30-16.45 The Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience E. Maragouli Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer 17.00-17.15 High-dose sequential chemotherapy (HDS) versus PEB Ι. Stoupis chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study 06 SATURDAY, May 28th, 2016 09.00-10.00 Session 9: Colorectal tumors Moderator: T. Makatsoris, A. Christopoulou 09.00-09.15 Maintenance treatment with capecitabine and M. Theochari bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer 09.15-09.30 Pathological responses after angiogenesis or EGFR V. Ramfidis inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab 07

09.30-09.45 Prognosis of stage II and III colon cancer treated with D. Repana adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial Bevacizumab plus mfolfox-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial 09.45-10.00 10.00-11.15 Session 10: Breast and Gynecological cancer Moderators: Ch. Papadimitriou, Ε. Timotheadou 10.00-10.15 The cyclin-dependent kinase 4/6 inhibitor palbociclib in S. Peroukidis combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials 10.15-10.30 Adjuvant denosumab in breast cancer (ABCSG-18): S. Karageorgopoulou a multicentre, randomised, double-blind, placebo-controlled trial Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 10.30-10.45 Primary Results of ROSE/TRIO-12, a Randomized E. Moirogiorgou Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine 10.45-11.00 Cediranib combined with carboplatin and paclitaxel in K. Stouraiti patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer 11.00-11.15 11.15-11.45 Coffee break 08 12.15-13.15 Session 11. Immuno-oncology and immunotherapy Moderator: A. Kotsakis, O. Tsitsilonis 12.15-12.30 Significance of Programmed Cell Death-Ligand 1 Κ. Koutsoukos Expression and its Association with Survival in Patients with Small Cell Lung Cancer PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes 12.30-12.45 Prognostic and predictive value of tumor-infiltrating G. Tsironis lymphocytes in two phase III randomized adjuvant breast cancer trials Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor 12.45-13.00 BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth M. Liontos The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4 13.00-13.15 13.15-14.30 Lunch 14.30-17.00 Session 12: HNC/Lung Cancer Moderator: V. Georgoulias, A. Argiris 14.30-14.45 TEMHEAD: a single-arm multicentre phase II study of P. Katsaounis temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO) Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing 14.45-15.00 A Bayesian network meta-analysis comparing concurrent E. Lianos chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer 4 cm in size: an SEER Medicare analysis 15.00-15.15 Non Small Cell Lung Cancer: A Phase II Global Study D. Doufexis a randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial 09

Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non Small-Cell Lung Cancer 15.15-15.30 Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma E. Biziota Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. 15.30-15.45 First-line erlotinib versus gemcitabine/cisplatin in patients A. Mala with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer 15.45-16.00 Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung A. Korogiannos Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort 16.00-16.15 Randomized, Double-Blind, Placebo-Controlled, M. Stratigos Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination with Either Docetaxel or Pemetrexed in Patients with Biomarker-Selected Non Small-Cell Lung Cancer Impact of a Contralateral Tumor Nodule on Survival in Non Small-Cell Lung Cancer 16.15-16.30 Postoperative Radiotherapy is Associated with G. Filippou Better Survival in Non Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the National Cancer Data Base Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial 18.15-19.45 Session 13: General Issues ΙΙ Moderator: M. Trichas, Ch. Christofyllakis 18.15-18.45 Building a global consensus approach to chordoma: I. Athanasiadis a position paper from the medical and patient community Management of primary retroperitoneal sarcoma (RPS) in the adult: A consensus approach from the Trans-Atlantic RPS working Group 18.45-19.00 Alectinib in Crizotinib-Refractory ALK-Rearranged Non Small-Cell Lung Cancer: A Phase II Global Study G. Kesisis Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer: Results from the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial 19.00-19.15 A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer A. Voutsina A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo 19.15-19.30 Cetuximab and Radiotherapy Versus Cisplatin and I. Georgakopoulos Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial Role of Chemoradiotherapy in Elderly Patients with Limited-Stage Small-Cell Lung Cancer 19.30-19.45 Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma P. Oikonomopoulou Genomic classification of cutaneous melanomas 19.30-19.45 19.45-20.00 Closing remarks 16.30-16.45 Bolstering the Case for Lobectomy in Stages I, II, and E. Kontopodis IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Surgical Management of Recurrent Thymic Epithelial Tumors: A Retrospective Analysis Based on the Japanese Nationwide Database 16.45-17.00 17.00-18.15 Coffee break 10 11

Ευρετήριο Ομιλητών - Προέδρων Argiris A. MD, PhD, FACP, Professor of Medical Oncology, Hygeia Hospital, Athens, & Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, USA Athanasiadis I. Medical Oncologist, Director of Oncology Clinic, MITERA Hospital- Hygeia Group, Athens, Bakogeorgos M. Medical Oncologist, Oncology Clinic, 251 General Airforce Hospital, Athens, Bamias A. MD, PhD MRCP, Associate professor, Medical school, National & Kapodistrian University of Athens, Biziota E. MD, PHD, Resident of Medical Oncology, University Hospital of Evros, Boukovinas I. MD, PhD, PharmaD, Medical Oncologist, Head of Oncology Unit, Bioclinic Thessaloniki, Boussios S. MD, PhD candidate Medical Oncologist, Clinical Research Fellow, Department of Medical Oncology, Ioannina University Hospital, Christofyllakis Ch. Director of the Department of Medical Oncology, 401 General Military Hospital of Athens, Christopoulou A. Medical Oncologist, Director of Oncology Unite, St Andrews General Hospital, Patra, Dimitriadis J. MD, MSc, Medical Oncology Resident, Department of Clinical Therapeutics, «Alexandra» Hospital, University of Athens Medical School, Athens, Doufexis D. Consultant in Medical Oncology, Larissa General Hospital, Kostouros Eft. Medical Oncologist, Ocology department, Therapeutics Clinic, University of Athens, Kotsakis A. Assistant Professor of Medical Oncology, University Hospital of Heraklion & Laboratory of Translational Oncology, University of Crete, School of Medicine, Crete, Koumarianou A. MD, PhD in Tumor Immunotherapies, Imperial College Consultant in Medical Oncology, Hematology-Oncology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Koutras A. Assistant Professor of Medical Oncology, University of Patras, Koutsopoulos A. MD, PhD, Assistant Professor of Pathology, Faculty of Medicine, University of Crete, Laboratory of Pathology, University Hospital of Heraklion, Crete, Koutsoukos Κ. Medical Oncologist Oncology Unit Dept. of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, Laschos K. Medical Oncologist Consultant, 2nd Department of Medical Oncology Clinic, GONK, Athens, Laskarakis A. Medical Oncologist MD, MSc, Consultant at 1st Oncology Clinic Metropolitan Hospital of Athens, Lianidou E. Professor of Analytical Chemistry Clinical Chemistry Laboratory of Analytical Chemistry Analysis of Circulating Tumor Cells (ACTC) Lab, Dept of Chemistry University of Athens, Lianos E. MD, Consultant of Medical Oncology, Dpt METAXA Memorial Cancer Center Hospital, Piraeus - Emmanouilides Ch. Medical Oncologist, Interbalkan Medical Center, Thessaloniki, Liontos M. MD, PhD Medical Oncologist, Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, Athens, Filippou G. Radiation Oncologist, Iatropolis Cyberknife and Tomotherapy Department, Athens, Loga K. MD, MSc, Resident of Clinical Oncology, Theageneion Cancer Hospital, Thessaloniki, Fotopoulos G. Medical Oncology Consultant, MD, PhD Candidate, Sotiria General Hospital, 3rd Department of Medicine, Medical School, University of Athens, Makatsoris Th. MD, PhD, Assistant Professor of Medical Oncology, University of Patras Medical School, Georgakopoulos I. Radiation Oncologist, Scientific Associate, IASO, Athens, Mala A. Resident in Medical Oncology, University Hospital of Heraklion, Crete, Georgoulias V. Emeritus Professor of Medical Oncology, School of Medicine, University of Crete Maragouli E. MD, Medical Oncologist, University of Thessaly & Biologist, Aristotle University of Thessaloniki, Karageorgopoulou S. MD, Medical Oncologist, Μedical Oncology Department, IASO, Athens, Mοirogiorgou E. MD, MSc, Medical Oncologist at Athens Medical Center, Katopodis O. MD, PhD, Consultant Medical Oncologist, Department of Medical Oncology, Athens Euroclinic, Katsaounis P. MD, Medical Oncologist, 1st Oncology Unit, IASO General, Athens, Kentepozidis N. Medical Oncologist, Head of Oncology Clinic, 251 General Airforce Hospital, Athens, Nikolaou M. Medical Oncologist in University Internal Medicine Department at HIPPOCRATION General Hospital of Athens, Ntouvelis Ε. MD, PhD, Medical Oncologist, Corfu General Clinic, Oikonomopoulos G. MSc, Consultant Medical Oncologist, Metropolitan Hospital of Athens, Kesisis G. Medical Oncologist, Agios Loukas Clinic, Thessaloniki, Oikonomopoulou P. MD, PhD, Medical Oncologist, Attikon Universtity Hospital, Athens, Koinis F. Medical Oncologist, Dpt of Medical Oncology, University Hospital of Heraklion, Crete, Panopoulos Ch. MD, PhD, Medical Oncologist, Consultant Head of Departement of Medical Oncology, EUROCLINIC, Athens, Kontopodis E. Medical Oncologist, Venizeleion General Hospital of Heraklion, Crete, Papadimitriou Ch. Professor of Medical Oncology, Medical School, National and Kapodistrian University of Athens, Korogiannos A. Resident in Medical Oncology, St. Savvas anti-cancer Ηospital, Athens, 12 13

Peroukidis S. M.D, M.Sc, Ph.D, Medical Oncologist, University Hospital of Patras, Pistamaltzian N. MD, PhD Medical Oncologist Consultant, Oncology Department, MITERA Hospital, Athens, Ploiarchopoulou K. Medical Oncologist, Euroclinic Athens, Γενικές Πληροφορίες Οργάνωση Ελληνική Ογκολογική Ερευνητική Ομάδα Λομβάρδου 55, Γκυζή Τηλ.: 210 6448450 Email: eoeo@horg.gr Polyzos A. Professor of Medical Oncology, School of Medicine, University of Athens, Ramfidis B. MD, MSc, Consultant Medical Oncologist, Department of Medical Oncology, 251 Airforce General Hospital of Athens, Rapti K. Resident in Medical Oncology, St.Savvas anti-cancer Ηospital, Athens, Repana D. Clinical Fellow in Medical Oncology, Guy s and St.Thomas NHS Foundation Trust London, UK Saloustros E. MD,DSc, Oncology Unit, General hospital of Heraklion Venizelio, Crete, Stoupis G. Fellow in Medical Oncology, Dpt of Medical Oncology, University General Hospital of Heraklion, Crete, Stouraiti K. Medical oncologist, Euroclinic Athens, Stratigos M. MD, Resident in Medical Oncology, University Hospital of Heraklion, Crete, Τόπος Διεξαγωγής Ξενοδοχείο Royal Olympic 28-34 Αθανασίου Διάκου 117 43, Αθήνα Τηλ.: +30 210 92.88.400 Fax.: +30 210 92.33.317 E-mail: info@royalolympic.com Ημερομηνία Διεξαγωγής Theochari M. MD, Consultant B of Medical Oncology, Oncology Unit, Hippokrateion University Hospital of Athens, 27-28 Μαΐου 2016 Timotheadou E. Assistant Professor of Medicine Oncology, Aristotle University of Thessaloniki, Συμμετοχή Το κόστος εγγραφής στη Διημερίδα είναι δωρεάν Trichas M. Radiation Oncologist, Research Associate IASO, Athens, Tsigaridas K. Medical Oncologist, A Oncology Unit, Metropolitan Hospital of Athens, Πιστοποιητικό Παρακολούθησης Tsironis G. MD, MSc, Medical Oncology Resident, Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Medical School, Athens, Tsitsilonis O. MD, PhD, Assoc. Professor of Immunology, Faculty of Biology, National & Kapodistrian University of Athens, Το πιστοποιητικό παρακολούθησης θα δοθεί στους συμμετέχοντες σε ηλεκτρονική μορφή, μετά το πέρας των εργασιών της Διημερίδας. Παρακαλούνται οι συμμετέχοντες όπως ενημερώσουν τη Γραμματεία με τα απαραίτητα στοιχεία επικοινωνίας προκειμένου να διασφαλιστεί η έγκαιρη αποστολή του πιστοποιητικού παρακολούθησης. Tsoukalas N. MD, MSc, PhD, Medical Oncologist, MSc in Bioinformatics Clinical Research Fellow in Oncology Guy s and St Thomas Cancer Centre NHS, London UK Η Διημερίδα αξιολογείται με 12 μόρια Συνεχιζόμενης Ιατρικής Εκπαίδευσης (CME CPD credits) που χορηγούνται από τον Πανελλήνιο Ιατρικό Σύλλογο (Π.Ι.Σ.). Tzovaras A. Medical Oncologist, PhD, Hippokrateion University Hospital, Athens, Vaslamatzis Μ. Director of the Departement of Medical Oncology, Enangelismos General Hospital of Athens, Γραμματεία Συνεδρίου Voulgaris E. MD, PhD, Consultant Medical Oncologist, Department of Medical Oncology, 424 Military Hospital,Thessaloniki, Scientific Ι Cultural Events and Publications T +30 210 7240039 F +30 210 7240139 E info@scep.gr www.scep.gr Voutsina A. MSc, PhD Research Associate, Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Xynogalos S. Medical Oncologist, Dpt of Medical Oncology, General Hospital «G. Genimatas», Athens, Zagouri F. MD, PhD, Medical Oncologist, Alexandra Hospital, Athens, 14 15

Sponsors Notes 16

Scientific Ι Cultural Events and Publications T +30 210 7240039 F +30 210 7240139 E info@scep.gr www.scep.gr